公开(公告)号：US20170247382A1

公开(公告)日：2017-08-31

申请号：US15457774

申请日：2017-03-13

申请人： University of Pittsburgh - Of the Commonwealth System of Higher Education

发明人： Zhou Wang ,  Joel Byron Nelson ,  Minh Bao Nguyen ,  John S. Lazo ,  Paul A. Johnston ,  Peter Wipf

IPC分类号： C07D487/04 ,  C07D471/08

CPC分类号： A61K31/496 ,  A61K31/407 ,  A61K31/4188 ,  A61K31/495 ,  A61K31/4965 ,  A61K31/58 ,  A61K45/06 ,  C07D235/02 ,  C07D241/04 ,  C07D261/04 ,  C07D261/08 ,  C07D295/16 ,  C07D401/04 ,  C07D403/04 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D471/08 ,  C07D487/04 ,  A61K2300/00

摘要： A method for treating prostate cancer in a subject, comprising administering a therapeutically effective amount of at least one agent to the subject, wherein the agent is selected from: (a) a phenyl-substituted imidazole, or a pharmaceutically acceptable salt or ester thereof; or (b) a compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of: wherein R20 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; R21 is an alkanediyl or a substituted alkanediyl; a is 0 or 1; c is 0 or 1; X is C or S; R22 is a moiety that includes at least one divalent amino radical; and R23 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group.

公开(公告)号：US10004730B2

公开(公告)日：2018-06-26

申请号：US15457782

申请日：2017-03-13

申请人： University of Pittsburgh-Of the Commonwealth System of Higher Education

发明人： Zhou Wang ,  Joel Byron Nelson ,  Minh Bao Nguyen ,  John S. Lazo ,  Paul A. Johnston ,  Peter Wipf

IPC分类号： A61K31/69 ,  A61K31/66 ,  A61K31/497 ,  A61K31/4965 ,  A61K31/415 ,  A61K31/16 ,  A61K31/496 ,  A61K31/4188 ,  A61K31/495

CPC分类号： A61K31/496 ,  A61K31/407 ,  A61K31/4188 ,  A61K31/495 ,  A61K31/4965 ,  A61K31/58 ,  A61K45/06 ,  C07D235/02 ,  C07D241/04 ,  C07D261/04 ,  C07D261/08 ,  C07D295/16 ,  C07D401/04 ,  C07D403/04 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D471/08 ,  C07D487/04 ,  A61K2300/00

摘要： A method for treating prostate cancer in a subject, comprising administering a therapeutically effective amount of at least one agent to the subject, wherein the agent is selected from: (a) a phenyl-substituted imidazole, or a pharmaceutically acceptable salt or ester thereof; or (b) a compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of:  wherein R20 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; R21 is an alkanediyl or a substituted alkanediyl; a is 0 or 1; c is 0 or 1; X is C or S; R22 is a moiety that includes at least one divalent amino radical; and R23 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group.

公开(公告)号：US09981974B2

公开(公告)日：2018-05-29

申请号：US15457774

申请日：2017-03-13

申请人： University of Pittsburgh—Of the Commonwealth System of Higher Education

发明人： Zhou Wang ,  Joel Byron Nelson ,  Minh Bao Nguyen ,  John S. Lazo ,  Paul A. Johnston ,  Peter Wipf

IPC分类号： C07D487/04 ,  C07D471/08

CPC分类号： A61K31/496 ,  A61K31/407 ,  A61K31/4188 ,  A61K31/495 ,  A61K31/4965 ,  A61K31/58 ,  A61K45/06 ,  C07D235/02 ,  C07D241/04 ,  C07D261/04 ,  C07D261/08 ,  C07D295/16 ,  C07D401/04 ,  C07D403/04 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D471/08 ,  C07D487/04 ,  A61K2300/00

摘要： A method for treating prostate cancer in a subject, comprising administering a therapeutically effective amount of at least one agent to the subject, wherein the agent is selected from: (a) a phenyl-substituted imidazole, or a pharmaceutically acceptable salt or ester thereof; or (b) a compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of: wherein R20 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; R21 is an alkanediyl or a substituted alkanediyl; a is 0 or 1; c is 0 or 1; X is C or S; R22 is a moiety that includes at least one divalent amino radical; and R23 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group.

公开(公告)号：US20170246164A1

公开(公告)日：2017-08-31

申请号：US15457782

申请日：2017-03-13

申请人： University of Pittsburgh - Of the Commonwealth System of Higher Education

发明人： Zhou Wang ,  Joel Byron Nelson ,  Minh Bao Nguyen ,  John S. Lazo ,  Paul A. Johnston ,  Peter Wipf

IPC分类号： A61K31/496 ,  A61K31/495 ,  A61K31/4188

CPC分类号： A61K31/496 ,  A61K31/407 ,  A61K31/4188 ,  A61K31/495 ,  A61K31/4965 ,  A61K31/58 ,  A61K45/06 ,  C07D235/02 ,  C07D241/04 ,  C07D261/04 ,  C07D261/08 ,  C07D295/16 ,  C07D401/04 ,  C07D403/04 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D471/08 ,  C07D487/04 ,  A61K2300/00

摘要： A method for treating prostate cancer in a subject, comprising administering a therapeutically effective amount of at least one agent to the subject, wherein the agent is selected from: (a) a phenyl-substituted imidazole, or a pharmaceutically acceptable salt or ester thereof; or (b) a compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of: wherein R20 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; R21 is an alkanediyl or a substituted alkanediyl; a is 0 or 1; c is 0 or 1; X is C or S; R22 is a moiety that includes at least one divalent amino radical; and R23 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group.

公开(公告)号：US11111253B2

公开(公告)日：2021-09-07

申请号：US16846089

申请日：2020-04-10

申请人： UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

发明人： Donna M. Huryn ,  Peter Wipf ,  Jennifer Rubin Grandis ,  Matthew G. LaPorte ,  Paul A. Johnston ,  Mark E. Schurdak ,  Raffaele Colombo

IPC分类号： C07D513/04 ,  A61P35/00

摘要： Compounds that selectivity inhibit the STAT3 pathway and not the STAT1 pathway and exhibit anti-proliferative activity are disclosed. Also disclosed are methods of treatment of cancers that are characterized by overexpression of STAT3, which are safer that other therapies.

公开(公告)号：US20200339602A1

公开(公告)日：2020-10-29

申请号：US16846089

申请日：2020-04-10

申请人： University of Pittsburgh - Of the Commonwealth System of Higher Education

发明人： Donna M. Huryn ,  Peter Wipf ,  Jennifer Rubin Grandis ,  Matthew G. LaPorte ,  Paul A. Johnston ,  Mark E. Schurdak ,  Raffaele Colombo

IPC分类号： C07D513/04 ,  A61P35/00

摘要： Compounds that selectivity inhibit the STAT3 pathway and not the STAT1 pathway and exhibit anti-proliferative activity are disclosed. Also disclosed are methods of treatment of cancers that are characterized by overexpression of STAT3, which are safer that other therapies.

公开(公告)号：US20190100535A1

公开(公告)日：2019-04-04

申请号：US15543573

申请日：2016-01-15

申请人： UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

发明人： Donna M. Huryn ,  Peter Wipf ,  Jennifer Rubin Grandis ,  Matthew G. LaPorte ,  Paul A. Johnston ,  Mark E. Schurdak ,  Raffaele Colombo

IPC分类号： C07D513/04 ,  A61P35/00

摘要： Compounds that selectivity inhibit the STAT3 pathway and not the STAT1 pathway and exhibit anti-proliferative activity are disclosed. Also disclosed are methods of treatment of cancers that are characterized by overexpression of STAT3, which are safer that other therapies.

公开(公告)号：US09708276B2

公开(公告)日：2017-07-18

申请号：US14351126

申请日：2012-10-10

申请人： University of Pittsburgh—Of the Commonwealth System of Higher Education

发明人： Zhou Wang ,  Joel Byron Nelson ,  Minh Mindy Bao Nguyen ,  John S. Lazo ,  Paul A. Johnston ,  Peter Wipf

IPC分类号： A61K31/407 ,  A61K31/496 ,  C07D261/08 ,  C07D295/16 ,  A61K31/495 ,  C07D401/04 ,  C07D235/02 ,  C07D403/04 ,  C07D409/04 ,  C07D413/04 ,  C07D241/04 ,  C07D417/04 ,  C07D261/04 ,  A61K31/4188 ,  A61K31/58 ,  A61K31/4965 ,  A61K45/06 ,  C07D487/04

CPC分类号： A61K31/496 ,  A61K31/407 ,  A61K31/4188 ,  A61K31/495 ,  A61K31/4965 ,  A61K31/58 ,  A61K45/06 ,  C07D235/02 ,  C07D241/04 ,  C07D261/04 ,  C07D261/08 ,  C07D295/16 ,  C07D401/04 ,  C07D403/04 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D471/08 ,  C07D487/04 ,  A61K2300/00

摘要： A method for treating prostate cancer in a subject, comprising administering a therapeutically effective amount of at least one agent to the subject, wherein the agent is selected from: (a) a phenyl-substituted imidazole, or a pharmaceutically acceptable salt or ester thereof; or (b) a compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of: wherein R20 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; R21 is an alkanediyl or a substituted alkanediyl; a is 0 or 1; c is 0 or 1; X is C or S; R22 is a moiety that includes at least one divalent amino radical; and R23 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group.